ATXI Plunges On Thumbs-down, VYGR's Huntington's Disease Trial On Hold, Deal Or No Deal For SURF?

Today's Daily Dose brings you news about FDA declining approval for Avenue Therapeutics/Fortress Biotech's pain drug IV Tramadol, encouraging data from Gilead/ Galapagos' Ulcerative Colitis trial, reports of Surface Oncology receiving a takeover offer from GlaxoSmithKline, and clinical hold slapped by the FDA on Voyager's Huntington's disease trial.

from RTT - Biotech https://ift.tt/2GZyIco
via IFTTT